spacer
home > epc > autumn 2003 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

I am writing this Editor's Letter in the middle of a British heatwave; and this time we really can call it a heatwave, with temperatures soaring over 30oC, and railway lines buckling! Temperatures are currently similar to those in San Antonio in June, where the 39th Annual DIA meeting was held. This meeting continues to grow in size, and this year it was bigger than ever, my only complaint being that there wasn't enough time to visit all the exhibition stands and attend all but a sample of the sessions.

I did, however, attend several of the sessions relating to outsourcing, but was disappointed that there seems to be little progress in improving the relationship between CRO and sponsor. The 'Preferred Provider Tug of War' was one title, which gives an idea of how the relationship is often viewed. The presentations supporting this title addressed how to make

it less of a struggle, and in a different session, classified as R&D Strategy, we heard about a strategic partnership between Solvay and Quintiles, which highlights how the sponsor/CRO relationship can develop to the benefit of both parties.

Included in this issue we have an article by Blair McCallum of McKinsey that describes the assessments of the benefits of outsourcing. While this article focuses on manufacturing, the 10 commandments given at the end could apply to any outsourcing relationship. The keys are clear communication, understanding the value proposition and clearly stated plans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

spacer
By Julia Lloyd-Parks
spacer
Julia Lloyd-Parks
spacer
spacer
spacer
John White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement